By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801



Company News
Orexigen (OREX) To Speak At The Rodman & Renshaw 18th Annual Global Investment Conference 9/8/2016 10:05:34 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Valeant Canada For Contrave (Naltrexone Hcl / Bupropion Hcl Extended Release) 8/30/2016 9:00:07 AM
Orexigen (OREX) Reports Business And Financial Results For The Second Quarter Ended June 30, 2016 8/5/2016 7:39:11 AM
Orexigen (OREX) Completes Acquisition Of All U.S. Rights To Contrave And Launches U.S. Sales Organization 8/1/2016 7:36:27 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Laboratorios FarmaceยดUticos Rovi, S.A. For Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) In Spain 8/1/2016 7:35:31 AM
Orexigen (OREX) To Provide Business Update And Discuss Second Quarter 2016 Financial Results On August 4, 2016 7/22/2016 6:28:59 AM
Orexigen (OREX) Announces Stockholder Approval Of All Proposals At 2016 Annual Meeting And Reverse Stock Split 7/11/2016 6:28:21 AM
Orexigen (OREX) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 6/23/2016 6:22:54 AM
San Diego's Orexigen (OREX) Names a New CFO and COO 6/9/2016 5:56:34 AM
Orexigen (OREX) Reports Favorable Markman Ruling In Contrave Patent Litigation 6/8/2016 7:54:52 AM